Abstract:Crohn's disease (CD) is an inflammatory bowel disease (IBD) sub-type characterized by transmural chronic inflammation of the gastrointestinal tract. Research indicates a complex CD etiology involving genetic predisposition and immune dysregulation in response to environmental triggers. The chronic mucosal inflammation has been associated with a dysregulated state, or dysbiosis, of the gut microbiome (bacteria), mycobiome (fungi), virome (bacteriophages and viruses), and archeaome (archaea) further affecting the interkingdom syntrophic relationships and host metabolism. Microbiota dysbiosis in CD is largely described by an increase in facultative anaerobic pathobionts at the expense of strict anaerobic Firmicutes, such as Faecalibacterium prausnitzii. In the mycobiome, reduced fungal diversity and fungal-bacteria interactions, along with a significantly increased abundance of Candida spp. and a decrease in Saccharomyces cerevisiae are well documented. Virome analysis also indicates a significant decrease in phage diversity, but an overall increase in phages infecting bacterial groups associated with intestinal inflammation. Finally, an increase in methanogenic archaea such as Methanosphaera stadtmanae exhibits high immunogenic potential and is associated with CD etiology. Common anti-inflammatory medications used in CD management (amino-salicylates, immunomodulators, and biologics) could also directly or indirectly affect the gut microbiome in CD. Other medications often used concomitantly in IBD, such as antibiotics, antidepressants, oral contraceptives, opioids, and proton pump inhibitors, have shown to alter the gut microbiota and account for increased susceptibility to disease onset or worsening of disease progression. In contrast, some environmental modifications through alternative therapies including fecal microbiota transplant (FMT), diet and dietary supplements with prebiotics, probiotics, and synbiotics have shown potential protective effects by reversing microbiota dysbiosis or by directly promoting beneficial microbes, together with minimal long-term adverse effects. In this review, we discuss the different approaches to modulating the global consortium of bacteria, fungi, viruses, and archaea in patients with CD through therapies that include antibiotics, probiotics, prebiotics, synbiotics, personalized diets, and FMT. We hope to provide evidence to encourage clinicians and researchers to incorporate these therapies into CD treatment options, along with making them aware of the limitations of these therapies, and indicate where more research is needed.

Role of gut microbiota in Crohn's disease pathogenesis: Insights from fecal microbiota transplantation in mouse model

Microbiota in Mesenteric Adipose Tissue from Crohn's Disease Promote Colitis in Mice

Transplant of microbiota from Crohn's disease patients to germ-free mice results in colitis

Dysbiosis of the Fecal Microbiota in the TNBS-induced Crohn’s Disease Mouse Model

Gut microbiome, metabolome, host immunity associated with inflammatory bowel disease and intervention of fecal microbiota transplantation

Identification of key taxa that favor intestinal colonization of Clostridium difficile in an adult Chinese population

Two Distinct Metacommunities Characterize the Gut Microbiota in Crohn'S Disease Patients

Fecal Microbiota Transplantation (FMT) Alleviates Experimental Colitis in Mice by Gut Microbiota Regulation

Integrative Multi-Omics Deciphers the Spatial Characteristics of Host-Gut Microbiota Interactions in Crohn’s Disease

Fecal microbiota transplantation ameliorates experimental colitis via gut microbiota and T-cell modulation

Dysbiosis of gut fungal microbiota is associated with mucosal inflammation in Crohn's disease.

Manipulation of Gut Microbiota as a Key Target for Crohn's Disease

Microbial Changes Associated with IBD Mouse Model and Microbiota Transplantation Confers Colitis Symptom in Microbiota Deletion Mice

Protective Role of Fecal Microbiota Transplantation on Colitis and Colitis-Associated Colon Cancer in Mice Is Associated With Treg Cells

Fecal Microbiota Transplant via Endoscopic Delivering Through Small Intestine and Colon: No Difference for Crohn’s Disease

Molecular-Phylogenetic Characterization of the Microbiota in Ulcerated and Non-Ulcerated Regions in the Patients with Crohn's Disease

Fecal fungal microbiota alterations associated with clinical phenotypes in Crohn’s disease in southwest China

Multiomics reveals microbial metabolites as key actors in intestinal fibrosis in Crohn’s disease

Changes of the fungal microbiota in inflamed intestinal mucosa of the patients with Crohn's disease

Fecal Fungal Microbiota Alterations Associated with Clinical Phenotypes in Crohn's Disease in Southwest China.

Fecal microbiota transplantation modulates the intestinal microbiome and alleviates Escherichia coli infected outcomes in mice